What adverse effects and monitoring considerations should be observed when administering intravenous immunoglobulin (IVIG)?

What to Watch Out for When Giving IVIG

Monitor renal function, ensure adequate hydration, infuse slowly, and watch for thrombotic events—these are the most critical safety measures when administering IVIG. 1

Critical Pre-Infusion Assessment

Before initiating IVIG, assess the following high-risk factors:

• Renal function: Measure BUN and serum creatinine baseline 1
• Volume status: Ensure patient is adequately hydrated before infusion 1
• IgA deficiency with anti-IgA antibodies: Contraindicated due to anaphylaxis risk, though this is extremely rare 2
• Thrombotic risk factors: Advanced age (>65), diabetes, cardiovascular disease, hypercoagulable states, paraproteinemia, indwelling catheters, prolonged immobilization, estrogen use 1
• Blood viscosity: Consider baseline assessment in patients with cryoglobulins, high triglycerides, or monoclonal gammopathies 1

Major Adverse Events to Monitor

Renal Dysfunction/Failure

Acute renal failure is one of the most serious complications, particularly with sucrose-containing products (though modern formulations often avoid sucrose). 1

• Occurs 1-10 days post-infusion 3
• Risk factors: Pre-existing renal insufficiency, diabetes, age >65, volume depletion, sepsis, paraproteinemia, nephrotoxic drugs 1
• Mitigation: Use minimum effective dose and slowest infusion rate in at-risk patients 1
• Monitor renal function periodically during chronic therapy; 10% of patients may experience ≥20% decline in GFR over 12 months 4

Thrombosis

Thrombotic events (arterial and venous) can occur even without known risk factors. 1

• Older patients are particularly vulnerable 5
• Prevention: Ensure adequate hydration, use minimum dose/rate, monitor for signs/symptoms of thrombosis 1
• Assess blood viscosity in high-risk patients 1

Hemolysis

Hemolysis can occur, especially after high-dose infusions. 2

• Rare in replacement therapy but monitor if suspected 2
• In chronic therapy, 21% of patients may have ≥3 g/dL decline in hematocrit over 12 months, though clinical hemolysis is uncommon 4
• Monitor hematocrit during long-term therapy 4

Aseptic Meningitis Syndrome (AMS)

Symptoms begin within hours to 2 days post-infusion. 1

• Presentation: Severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, vomiting 1
• CSF shows pleocytosis (up to several thousand cells/mm³) with elevated protein but negative cultures 1
• Resolves within days after discontinuation 1

Hypersensitivity/Anaphylaxis

Severe reactions can occur even in patients who previously tolerated IVIG. 1

• IgA-deficient patients with anti-IgA antibodies have the highest risk, though reactions are extremely rare 2
• Some patients who react to IVIG may tolerate subcutaneous formulations 2
• Action: Discontinue immediately if hypersensitivity develops 1

Hyperproteinemia and Pseudohyponatremia

IVIG can cause increased serum viscosity and pseudohyponatremia. 1

• Critical distinction: True hyponatremia vs. pseudohyponatremia—treating pseudohyponatremia with fluid restriction worsens viscosity and thrombosis risk 1

Infusion Protocol

Start slowly and monitor vital signs throughout:

• Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min) 1
• If tolerated for 30 minutes, gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min) 1
• Slow or stop if adverse reactions occur; may resume at lower rate if symptoms resolve 1
• Most mild reactions (headache, flushing, nausea) respond to slowing infusion 6, 7

Ongoing Monitoring During Chronic Therapy

Regular laboratory monitoring is essential (minimum every 6-12 months, more frequently in children): 2

• IgG trough levels 2
• Complete blood counts (watch for cytopenias, hemolysis) 2
• Renal function (BUN, creatinine) 2, 1
• Liver enzymes (hepatitis risk is very low but monitor) 2

Common Pitfalls to Avoid

• Volume depletion: Always ensure adequate hydration before infusion 1
• Rapid infusion in high-risk patients: Use slowest rate possible in elderly, diabetic, or those with cardiovascular disease 1, 5
• Ignoring mild symptoms: Early headache or flushing may herald more serious reactions—slow the infusion 6, 7
• Permanent central lines for IVIG alone: Discouraged due to infection risk; consider subcutaneous route for difficult access 2